Evaluation of healthcare resource utilization and costs among patients diagnosed with extra-pulmonary neuroendocrine carcinoma (epNEC): a non-interventional multimodal database analysis in the US
AMCP 2026
C. Gay, N. Liu, E. Liu, A. Curran, L. DelGobbo, E. Scherrer, K. Vrieze, A. Christensen, S. Ijioma, N. Vijayvergia
Background
Extra-pulmonary neuroendocrine carcinomas(epNECs) are a rare and aggressive subset of neuroendocrineneoplasms, with an incidence rate of approximately 1 per100,000 individuals. They are associated with high morbidity and poor prognosis. Platinum-based chemotherapy is gener-ally accepted as the preferred first-line (1L) therapy, based onpractices from small cell lung cancer; however, there is noevidence-based recommendation or standard for second-line(2L) therapy. Furthermore, the healthcare resource utilization(HCRU) and economic impact of patients with epNEC has notbeen characterized.OBJECTIVE: To evaluate HCRU and costs among patients diag-nosed with epNEC in the US.METHODS: A retrospective study of patients diagnosed withepNEC from August 2012 to March 2025 was conducted usingthe Tempus multimodal dataset, linked to claims data from theKomodo Healthcare Map. The Tempus data model includesde-identified, longitudinal data across multiple cancer types,supporting a comprehensive analysis of this rare tumor.HCRU and cost outcomes were assessed as a per-patientper-month (PPPM) rate by line of therapy. All-cause costswere determined by applying standardized reference costsfrom the 2025 Medicare Fee Schedule.RESULTS: Of 146 epNEC patients identified, claims data wereavailable for 112 patients treated with 1L therapy. During 1Ltherapy, mean number of hospitalizations was 0.47 PPPM($924 PPPM), with a mean hospital stay of 2.28 days. The meannumber of outpatient visits, emergency room visits, and phar-macy claims was 4.75 PPPM ($4,185 PPPM), 0.10 PPPM ($57PPPM), and 4.74 PPPM ($2,636 PPPM), respectively. All othercosts during 1L therapy averaged $296 PPPM resulting inmean total all-cause costs of $8,099 PPPM in 1L. During 2Ltherapy (N=44), mean number of hospitalizations was 0.47PPPM ($1,001 PPPM), with a mean hospital stay of 3.37 days.The mean number of outpatient visits, emergency room visits,and pharmacy claims was 3.30 PPPM ($4,351 PPPM), 0.14 PPPM($132 PPPM), and 3.60 PPPM ($11,401 PPPM), respectively. Allother costs during 2L therapy averaged $116 PPPM resultingin mean total all-cause costs of $17,001 PPPM in 2L.CONCLUSIONS: Patients with epNEC face high HCRU and costburden across 1L and 2L therapy, mainly driven by outpatientvisits and pharmacy claims. Furthermore, despite lower phar-macy utilization and lack of standard therapy in 2L, totalall-cause costs more than doubled in 2L versus 1L due topharmacy claims.
Related publications